Sleep Cycle Q3 2026 slides: B2B hits 20%, margins rise amid sales drop

Sleep Cycle’s Q3 2026 net sales fell 17.3% to SEK 50.9 million, and paying subscribers declined 24% year over year to 605,000, while adjusted EBIT margin improved to 29.7% and B2B revenue rose 49.2% to approximately SEK 10 million. Management guided to an adjusted EBIT margin of about 20% for full-year 2026 and expects SEK 35 million in annual savings from restructuring. The proposed all-share Audiowell acquisition would create a combined company with illustrative 2025 pro forma sales of SEK 625 million and EBIT of SEK 282 million, but it remains subject to shareholder and regulatory approvals. Shares were reported at SEK 24.05, down 0.62% from the previous close.

Analysis

The key issue is earnings quality, not the adjusted margin headline: reported profitability is weighed down by one-offs, while capitalized development defers some product investment from current-period expense. If app acquisition does not recover, cost cuts can support margins temporarily without repairing the underlying revenue engine; any later impairment or slower-than-expected Apnea Alert monetization would expose that gap. B2B licensing is strategically valuable because partner distribution can reduce dependence on app-store discovery, but a small customer base makes growth vulnerable to a few renewal or rollout decisions. Treat current growth as proof of demand, not yet proof of a scalable channel.

The proposed share-funded Audiowell deal limits immediate cash outlay but shifts the investment case toward content economics, integration, and dilution. Its illustrative, unaudited financial profile is not directly comparable with Sleep Cycle’s reported results; verify transaction terms, accounting, and the target’s standalone cash conversion before assigning value. A new group CEO from the target also raises execution and governance questions during an already broad strategic pivot.

Near term, the November shareholder vote is the clearest event catalyst. Over 1–3 months, watch Q4 conversion and whether margin improvement is driven by durable efficiency or simply lower marketing. Over 6–18 months, the thesis hinges on app subscriber stabilization, repeatable SDK deployments, and regulatory/commercial progress for Apnea Alert. Apple and Alphabet may reinforce consumer expectations for bundled sleep tracking, but any direct earnings impact on those diversified platforms is immaterial; the competitive pressure is more consequential for Sleep Cycle’s acquisition funnel. Contrarian point: the cost program and B2B mix shift may be underappreciated, but the market may also be over-crediting unaudited acquisition economics and a large addressable market before clinical utility and willingness to pay are demonstrated.

Key Decisions for Investors

• Avoid chasing SLEEP on adjusted-margin improvement alone. Reassess after the November 11 vote and transaction disclosures; require clarity on share issuance, control, integration costs, and audited Audiowell financials before underwriting the pro forma earnings profile.
• For an existing SLEEP position, keep exposure sized as an execution situation rather than a proven growth compounder; use Q4 results to test whether subscriber conversion stabilizes while ARPU is maintained. A further deterioration in paying subscribers alongside weaker B2B additions would falsify the recovery case.
• Watch, rather than trade, the Apnea Alert opportunity until launch evidence emerges: regulatory status, validated performance, consumer conversion, and clinician follow-through matter more than registrations of interest. A delay beyond the early-2027 EU/UK plan or failure to progress toward Class IIa/FDA pathways weakens the upside case.
• Track cash conversion alongside reported EBIT and capitalized development. If development capitalization remains elevated while liquidity falls and commercial milestones slip, treat the margin narrative as lower quality; if licensing renewals broaden and subscriber declines moderate, the risk/reward improves.